NO-REFLOW PHENOMENON

Clinical trials for NO-REFLOW PHENOMENON explained in plain language.

Never miss a new study

Get alerted when new NO-REFLOW PHENOMENON trials appear

Sign up with your email to follow new studies for NO-REFLOW PHENOMENON, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 1 Completed 2

Diabetes drug could shield heart muscle during angioplasty

Disease control Ongoing

This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3…

Matched conditions: NO-REFLOW PHENOMENON

Phase: PHASE2 • Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez • Aim: Disease control

Last updated Jun 27, 2026 12:07 UTC

NO-REFLOW PHENOMENON

Get alerted when new NO-REFLOW PHENOMENON trials appear

Diabetes drug could shield heart muscle during angioplasty